🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524168-39-00
Completed Phase I

A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

2025-524168-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Stemline Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
23/03/2026
Enrollment target
23
Sites
Spain

Condition studied

​​Platinum-Resistant ovarian cancer​

Eligibility

Age group
65+ years, 18-64 years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524168-39-00 on CTIS ↗ ← All trials in the EU